QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC
Status:
Withdrawn
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Treatment with radiosurgery, temozolomide, and erlotinib may affect brain function
(the ability to think, learn, remember, and judge) in patients with non-small cell lung
cancer and brain metastases. A study that evaluates brain function may help doctors plan the
best treatment.
PURPOSE: This phase II trial is studying the effect of radiosurgery, temozolomide, and
erlotinib on brain function in patients with non-small cell lung cancer and brain metastases.
Phase:
Phase 2
Details
Lead Sponsor:
University of Medicine and Dentistry of New Jersey
Collaborators:
Genentech, Inc. National Cancer Institute (NCI) Schering-Plough